Tirzepatide Combined with Hormone Therapy Shows 35% Greater Weight Loss in Postmenopausal Women
Key Insights
A Mayo Clinic study of 120 postmenopausal women found that combining tirzepatide with hormone therapy resulted in 35% greater weight loss compared to tirzepatide alone over 12-18 months.
Women receiving both treatments lost an average of 17% of their body weight versus 14% for those using tirzepatide alone, with 45% achieving at least 20% weight loss compared to only 18% in the single-therapy group.
The findings, presented at ENDO 2025, represent the first study demonstrating enhanced efficacy of this combination therapy for postmenopausal weight management.
A Mayo Clinic study has revealed that postmenopausal women who combine tirzepatide with menopause hormone therapy experience significantly greater weight loss than those using tirzepatide alone. The research, presented at ENDO 2025, the Endocrine Society's annual meeting in San Francisco, showed a 35% increase in weight loss effectiveness when both treatments were used together.
Study Design and Methodology
The retrospective study analyzed medical records from 120 postmenopausal women with overweight or obesity (search) who received tirzepatide for 12 months or longer. Researchers compared 40 women who used both tirzepatide and hormone therapy with 80 women who used tirzepatide alone over approximately 18 months.
Dr. Regina Castaneda, a research fellow at the Mayo Clinic in Florida, noted this is the first study to demonstrate that combining these two treatments can enhance weight loss effectiveness for postmenopausal women.
Clinical Outcomes
The combination therapy group achieved markedly superior results across multiple weight loss metrics. Women receiving both treatments lost an average of 17% of their body weight, compared to 14% for those using tirzepatide alone. More notably, 45% of women on combination therapy achieved at least 20% body weight reduction, compared to only 18% of women using tirzepatide as monotherapy.
"The results are consistent with what we observe in bariatric practice — specifically, that postmenopausal hormonal changes can significantly impact a woman's weight," said Dr. Mir Ali, a bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center (search) at Orange Coast Medical Center in Fountain Valley, CA.
Therapeutic Context
Tirzepatide (Zepbound) is an FDA-approved GLP-1 (search) medication for weight management, also available as Mounjaro for type 2 diabetes (search) treatment. Menopause hormone therapy helps replenish ovarian hormones lost during the menopausal transition, addressing symptoms like hot flashes, night sweats, and weight gain that affect approximately three out of four women.
The hormonal changes during menopause can accelerate age-related weight gain and increase the likelihood of developing overweight or obesity (search), which are risk factors for type 2 diabetes (search) and cardiovascular disease (search). These changes often result in increased abdominal fat, reduced muscle mass, and slower metabolism.
Study Limitations and Future Directions
Senior study author Dr. Maria Daniela Hurtado Andrade, an endocrinologist at Mayo Clinic, emphasized important limitations: "Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss." She suggested that participants using hormone therapy may have already been engaged in healthier behaviors, or that relief from menopause symptoms may have improved quality of life, facilitating better adherence to physical activity and dietary changes.
Dr. Amy Roskin, a board-certified OB/GYN and Chief Medical Officer at Seven Starling (search), called the findings "interesting and encouraging," noting that "there haven't been many studies looking at how this class of medications might work together with hormone therapy."
Clinical Implications
The research offers new treatment possibilities for postmenopausal women struggling with weight management. Dr. Hurtado Andrade explained that the study helps clinicians "understand how to create better and more personalized weight-loss plans for women after menopause" and highlights the importance of making these treatments more accessible.
The findings align with similar results observed with semaglutide, another weight-loss medication, suggesting this enhanced efficacy may represent a broader trend with obesity (search) medications combined with hormone therapy.
Dr. Ali indicated that future research should focus on "specific dosages and optimal timing for hormone replacement therapy in postmenopausal women to optimize weight loss and health in general." Additional randomized controlled trials will be necessary to establish causation and optimize treatment protocols for this patient population.